Cardiogen vs Thymulin
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
- Half-Life
- Short (minutes); gene-regulatory effects persist longer
- ~30 minutes active half-life
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 20-30 mcg
- Frequency
- Daily for 10–30 days
- 10 days per month (Khavinson protocol)
- Key Benefits
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Enhances T-cell maturation and differentiation
- Boosts NK cell cytotoxic activity
- Reduces inflammatory cytokine production (TNF-α, IL-1)
- Anti-nociceptive (pain-reducing) properties
- Restores age-related immune decline
- Anti-inflammatory via serotonin pathway modulation
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Injection site reactions
- Mild fatigue initially as immune system activates
- Stacks With
- —
- —